Early buyers will receive 10% customization on this report.
Factors driving the growth of this market include rising R&D investment in the pharmaceutical & biotechnological companies, increasing number of cell culture studies in research institutes and rising government & non-profit organizations focus on chronic diseases research.
Enzymatic dissociation products are estimated to account for the largest share of the cell dissociation market in 2017.
The products in the cell dissociation market include enzymatic dissociation products, non-enzymatic dissociation products and instruments & accessories. In 2018, the enzymatic dissociation products segment is expected to hold the largest share of the market. Increasing demand for enzymatic dissociation products in the pharmaceutical & biotechnological companies is the major driving factor of this segment.
The pharmaceutical & biotechnology companies segment is estimated to grow at the highest CAGR during the forecast period.
The end user segment is further segmented into pharmaceutical & biotechnology companies, research & academic institutes, and other end users. The pharmaceutical & biotechnology segment is estimated to register highest growth rate during the forecast period. This is mainly due to rising R&D investments in order to introduce new drugs into the market.
North America is expected to command the largest share of the market during the forecast period.
Based on region, the cell dissociation market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the cell dissociation market in 2017. This is mainly due to factors such as the rising government funding for cancer research, increasing research on infectious diseases in the research institutes, rising R&D investments in the life sciences industry and presence of all key players in the region.
Key players in the cell dissociation market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Roche (Switzerland), Miltenyi Biotec (Germany), HiMedia Laboratories (India), STEMCELL Technologies (Canada), BD (US), ATCC (US), PAN-Biotech (Germany), and GE Healthcare (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: